Eric Suhler, MD
Uveitis and Ocular Inflammatory Disease · Portland, ORNPI 1275585143
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,410 of the $36,745 with a category attached, or 88.2%. 7 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 55.5% of the total.
Across 34 payments — averaging $1080.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$20K
- Merck$11K
- Regeneron$3K
- Roche Products Limited$2K
- Eyepoint US, Inc.$226
- Gilead$199
- plus $189 from 1 others
Across 61 payments — averaging $5338.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$153K
- Roche TCRC, Inc.$76K
- Gilead$52K
- Eyepoint US, Inc.$24K
- F. Hoffmann-la Roche AG$15K
- Alimera Sciences, Inc.$5K
What the payments were for
- Consulting fees$32,41088%
- Travel & lodging$3,0918%
- Food & beverage$1,2453%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 15 | $20,390 |
| Merck | 9 | $11,350 |
| Regeneron | 2 | $2,577 |
| Roche Products Limited | 1 | $1,815 |
| Eyepoint US, Inc. | 4 | $226 |
| Gilead | 2 | $199 |
| Genentech, Inc. | 1 | $189 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- YUTIQ$116
How this compares
Too few uveitis and ocular inflammatory disease providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $113,169 |
| Difluprednate | 12 | $2,384 |
| Prednisolone Acetate | 31 | $1,242 |
| Mycophenolate Mofetil | 16 | $763 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $315 |
| Prednisone | 20 | $179 |
Paid to pharmacies, not to this prescriber.
Other uveitis and ocular inflammatory disease in Portland
- Jason SkaletOregon City$34
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.